Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash & Current Investments (2019 - 2025)

Harmony Biosciences Holdings' Cash & Current Investments history spans 7 years, with the latest figure at $22.8 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 95.11% year-over-year to $22.8 million; the TTM value through Dec 2025 reached $59.7 million, down 87.22%, while the annual FY2025 figure was $22.8 million, 95.11% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $22.8 million at Harmony Biosciences Holdings, down from $672.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $672.6 million in Q3 2025 and bottomed at $17.6 million in Q2 2022.
  • The 5-year median for Cash & Current Investments is $346.4 million (2023), against an average of $298.3 million.
  • The largest annual shift saw Cash & Current Investments surged 2003.32% in 2023 before it crashed 95.11% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $234.3 million in 2021, then surged by 56.29% to $366.2 million in 2022, then decreased by 3.48% to $353.5 million in 2023, then skyrocketed by 32.18% to $467.2 million in 2024, then plummeted by 95.11% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Cash & Current Investments are $22.8 million (Q4 2025), $672.6 million (Q3 2025), and $19.2 million (Q2 2025).